TSFLAB02b:	Subjects With [Laboratory Category] Laboratory Values With Elevated or Low Values Meeting Specified Levels Over Time; Safety Analysis Set (Study jjcs - core)						
Time Point 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
  Laboratory Test 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
    Threshold Level, n (%) 	N=53 	N=73 	N=59 	  	  	
Cycle 02 	49 	63 	53 	 	 	
Calcium, low 	 	 	 	 	 	
N 	15 	16 	16 	 	 	
Level 1 (<2.096 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<1.996 mmol/L) 	0 	3 (18.8%) 	1 (6.2%) 	-6.2 (-18.1, 5.6) 	12.5 (-10.0, 35.0) 	
Level 3 (<1.871 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Glucose, low 	 	 	 	 	 	
N 	13 	19 	17 	 	 	
Level 1 (<3.89 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<3.00 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Cycle 03 	52 	50 	53 	 	 	
Calcium, low 	 	 	 	 	 	
N 	12 	14 	17 	 	 	
Level 1 (<2.096 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<1.996 mmol/L) 	0 	2 (14.3%) 	2 (11.8%) 	-11.8 (-27.1, 3.6) 	2.5 (-21.4, 26.4) 	
Level 3 (<1.871 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Glucose, low 	 	 	 	 	 	
N 	9 	11 	12 	 	 	
Level 1 (<3.89 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<3.00 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Cycle 04 	45 	45 	47 	 	 	
Calcium, low 	 	 	 	 	 	
N 	11 	16 	14 	 	 	
Level 1 (<2.096 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<1.996 mmol/L) 	3 (27.3%) 	1 (6.2%) 	2 (14.3%) 	13.0 (-19.1, 45.1) 	-8.0 (-29.9, 13.8) 	
Level 3 (<1.871 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Glucose, low 	 	 	 	 	 	
N 	11 	9 	11 	 	 	
Level 1 (<3.89 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<3.00 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0)